Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Aeterna Zentaris in a research note on Tuesday, March 28th.

Get Aeterna Zentaris alerts:

Aeterna Zentaris Stock Performance

Shares of NASDAQ AEZS opened at $2.92 on Wednesday. The stock has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $3.23. The firm has a market cap of $14.18 million, a P/E ratio of -0.58 and a beta of 1.35. Aeterna Zentaris has a 1 year low of $2.32 and a 1 year high of $8.63.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last issued its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.09. The firm had revenue of $2.49 million for the quarter, compared to the consensus estimate of $1.06 million. On average, research analysts predict that Aeterna Zentaris will post -3.41 earnings per share for the current fiscal year.

Aeterna Zentaris Company Profile

(Get Rating)

Æterna Zentaris, Inc is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Read More

• Get a free copy of the StockNews.com research report on Aeterna Zentaris (AEZS)
• Is American Airlines a Good Stock to Buy?
• High Dividend REITs: Are They an Ideal Way to Diversify?
• It Is Not Too Late To “Git” On Board With GitLab 
• Is Frontline’s 20% Dividend Too Good To Be True?
• Hospitality’s Rebound Has A Table At Cracker Barrel

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.